SCHEMBL3349351

SCHEMBL3349351

CCCOc1cccc(-c2c[nH]c(=S)[nH]2)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.49
GAA P10253 4/20 0.49
GFER P55789 1/20 0.49
MAPT P10636 5/20 0.42
KMT2A Q03164 3/20 0.42
MEN1 O00255 1/20 0.42
TDP1 Q9NUW8 3/20 0.42
THRB P10828 1/20 0.42
LMNA P02545 4/20 0.41
CYP1A2 P05177 2/20 0.41
CYP2C9 P11712 2/20 0.41
CYP2C19 P33261 2/20 0.41
ALOX12 P18054 2/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
ALDH1A1 P00352 3/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
HTT P42858 1/20 0.41
HDAC8 Q9BY41 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL639132 0.93 KDM4E (0.47) KDM4EGAAGFERMAPTKMT2A
SCHEMBL3633389 0.82 ERN1 (0.40) KDM4EGAAGFERMAPTKMT2A
SCHEMBL640473 0.81 GAA (0.56) KDM4EGAAGFERKMT2AMEN1
SCHEMBL3342864 0.77 CYP2D6 (0.54) KDM4EGAAGFERMAPTLMNA
SCHEMBL198917 0.77 KDM4E (0.59) KDM4EMAPTKMT2AMEN1CYP1A2
SCHEMBL638114 0.75 GFER (0.56) KDM4EGAAGFERMAPTLMNA
SCHEMBL638571 0.74 GFER (0.51) KDM4EGAAGFERMAPTKMT2A
SCHEMBL7369175 0.74 MAPT (0.54) KDM4EGAAMAPTKMT2AMEN1
SCHEMBL639362 0.72 GFER (0.61) KDM4EGAAGFERMAPTKMT2A
SCHEMBL3341441 0.72 GFER (0.61) KDM4EGAAGFERMAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100160401-A1 4-PHENYLIMIDAZOLE-2-THIONE TYROSINASE INHIBITORS AND TREATMENT OR PREVENTION OF PIGMENTARY DISORDERS THEREWITH GALDERMA RESEARCH & DEVELOPMENT, BIOT, FRANCE 2010-06-24 US claimed
US-20100160401-A1 4-PHENYLIMIDAZOLE-2-THIONE TYROSINASE INHIBITORS AND TREATMENT OR PREVENTION OF PIGMENTARY DISORDERS THEREWITH GALDERMA RESEARCH & DEVELOPMENT, BIOT, FRANCE 2010-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160401-A1 4-PHENYLIMIDAZOLE-2-THIONE TYROSINASE INHIBITORS AND TREATMENT OR PREVENTION OF PIGMENTARY DISORDERS THEREWITH TYR, TH, PAH KDM4E 1018/4885GAA 58/4885GFER 2509/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.